X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs UNICHEM LAB - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA UNICHEM LAB DISHMAN PHARMA/
UNICHEM LAB
 
P/E (TTM) x 25.1 -279.1 - View Chart
P/BV x 3.3 2.1 162.6% View Chart
Dividend Yield % 0.7 1.2 53.4%  

Financials

 DISHMAN PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
UNICHEM LAB
Mar-17
DISHMAN PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs374320 117.0%   
Low Rs129221 58.3%   
Sales per share (Unadj.) Rs197.8167.2 118.3%  
Earnings per share (Unadj.) Rs21.212.0 177.3%  
Cash flow per share (Unadj.) Rs34.716.9 205.1%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.81.1 71.6%  
Book value per share (Unadj.) Rs179.9117.0 153.7%  
Shares outstanding (eoy) m80.6990.88 88.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.6 78.7%   
Avg P/E ratio x11.922.6 52.5%  
P/CF ratio (eoy) x7.216.0 45.4%  
Price / Book Value ratio x1.42.3 60.5%  
Dividend payout %9.425.1 37.6%   
Avg Mkt Cap Rs m20,30624,578 82.6%   
No. of employees `0000.85.2 16.0%   
Total wages/salary Rs m5,3552,487 215.3%   
Avg. sales/employee Rs Th19,252.72,928.3 657.5%   
Avg. wages/employee Rs Th6,459.5479.4 1,347.5%   
Avg. net profit/employee Rs Th2,064.1209.4 985.5%   
INCOME DATA
Net Sales Rs m15,96115,195 105.0%  
Other income Rs m265110 240.8%   
Total revenues Rs m16,22615,305 106.0%   
Gross profit Rs m4,1031,788 229.5%  
Depreciation Rs m1,091452 241.4%   
Interest Rs m94434 2,802.4%   
Profit before tax Rs m2,3341,413 165.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624326 191.4%   
Profit after tax Rs m1,7111,087 157.4%  
Gross profit margin %25.711.8 218.5%  
Effective tax rate %26.723.1 115.9%   
Net profit margin %10.77.2 149.9%  
BALANCE SHEET DATA
Current assets Rs m11,0186,426 171.5%   
Current liabilities Rs m9,5173,917 242.9%   
Net working cap to sales %9.416.5 57.0%  
Current ratio x1.21.6 70.6%  
Inventory Days Days11068 163.3%  
Debtors Days Days3577 45.3%  
Net fixed assets Rs m16,3047,410 220.0%   
Share capital Rs m161182 88.8%   
"Free" reserves Rs m12,90710,454 123.5%   
Net worth Rs m14,51610,636 136.5%   
Long term debt Rs m4,1894 95,213.6%   
Total assets Rs m29,80515,258 195.3%  
Interest coverage x3.542.9 8.1%   
Debt to equity ratio x0.30 69,767.6%  
Sales to assets ratio x0.51.0 53.8%   
Return on assets %8.97.3 121.3%  
Return on equity %11.810.2 115.4%  
Return on capital %17.513.6 129.0%  
Exports to sales %24.824.1 102.7%   
Imports to sales %3.74.9 75.5%   
Exports (fob) Rs m3,9563,666 107.9%   
Imports (cif) Rs m596752 79.3%   
Fx inflow Rs m4,9525,298 93.5%   
Fx outflow Rs m6970-   
Net fx Rs m4,2555,298 80.3%   
CASH FLOW
From Operations Rs m2,786683 407.7%  
From Investments Rs m-1,529-1,316 116.2%  
From Financial Activity Rs m-941592 -158.9%  
Net Cashflow Rs m316-40 -793.0%  

Share Holding

Indian Promoters % 61.4 50.1 122.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 15.1 24.5%  
FIIs % 12.7 3.0 423.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 31.7 69.7%  
Shareholders   46,261 20,176 229.3%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   WOCKHARDT LTD.  J.B.CHEMICALS  MERCK LTD  BIOCON LTD  FULFORD INDIA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Cuts Losses; TCS Up 3%(Closing)

After opening the day in red, share markets in India witnessed volatile trading activity throughout the day but clawed back some gains in the final hours of the trading window.

Related Views on News

UNICHEM LAB Announces Quarterly Results (4QFY18); Net Profit Down 91.1%

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, UNICHEM LAB has posted a net profit of Rs 28 m (down 91.1% YoY). Sales on the other hand came in at Rs 2 bn (down 40.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - PANACEA BIOTECH COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS